Compare ETON & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETON | ITIC |
|---|---|---|
| Founded | 2017 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 517.1M |
| IPO Year | 2018 | N/A |
| Metric | ETON | ITIC |
|---|---|---|
| Price | $16.71 | $252.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $29.67 | N/A |
| AVG Volume (30 Days) | ★ 277.8K | 20.3K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 6.32% |
| EPS Growth | N/A | ★ 25.81 |
| EPS | N/A | ★ 19.00 |
| Revenue | $70,316,000.00 | ★ $273,864,000.00 |
| Revenue This Year | $113.27 | N/A |
| Revenue Next Year | $36.70 | N/A |
| P/E Ratio | ★ N/A | $13.19 |
| Revenue Growth | ★ 102.77 | 13.63 |
| 52 Week Low | $11.09 | $190.20 |
| 52 Week High | $23.00 | $288.98 |
| Indicator | ETON | ITIC |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 41.04 |
| Support Level | $16.13 | $237.90 |
| Resistance Level | $17.05 | $249.78 |
| Average True Range (ATR) | 0.76 | 7.71 |
| MACD | 0.16 | -2.57 |
| Stochastic Oscillator | 79.06 | 26.63 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.